University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Hala Borno, MD

Hala Borno, MD

Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

Dr. Hala Borno is a medical oncologist specializing in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Her academic interests include cancer disparities and digital health technologies that improve clinical trial participation. Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics. She is now faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. At HDFCCC, she is a member of the cancer committee, quality council, cancer control program, and prostate program. She is also a member of the American Society of Clinical Oncology and health disparities committee for Alliance for Clinical Trials in Oncology.

Education

University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Hammer MJ, Kenfield SA, Kober KM, Levine JD, Pozzar R, Rhoads KF, Van Blarigan EL, Van Loon K. STRESS AND SYMPTOM BURDEN IN ONCOLOGY PATIENTS DURING THE COVID-19 PANDEMIC. J Pain Symptom Manage. 2020 Sep 01.
    View on PubMed
  2. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K. Oncology patients' perceptions of and experiences with COVID-19. Support Care Cancer. 2020 Aug 18.
    View on PubMed
  3. Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urol Oncol. 2020 Aug 08.
    View on PubMed
  4. Borno HT, Zhang S, Gomez S. COVID-19 disparities: An urgent call for race reporting and representation in clinical research. Contemp Clin Trials Commun. 2020 Sep; 19:100630.
    View on PubMed
  5. Borno HT, Lin TK, Batniji RS. Determining the impact of Medicaid expansion on cancer burden. Cancer. 2020 Jul 06.
    View on PubMed
  6. DeRouen MC, McKinley M, Shah SA, Borno HT, Aoki R, Lichtensztajn DY, Leppert JT, Brooks JD, Chung BI, Gomez SL, Cheng I. Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes Control. 2020 Aug; 31(8):713-721.
    View on PubMed
  7. Hala Borno, Kelvin A. Moses, Paul Monk, Kate Fitch, Matthew Harmon, Scott Flanders, Rana R. McKay. Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17589-e17589.
    View on PubMed
  8. Barry Tong, Hala Borno, Eric Jay Small, Fern Alagala, Amie Blanco, Mallika Sachdev Dhawan. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1590-1590.
    View on PubMed
  9. Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S. Racial disparities and online health information: YouTube and prostate cancer clinical trials. BJU Int. 2020 Jul; 126(1):11-13.
    View on PubMed
  10. Borno HT, Small EJ. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemp Clin Trials. 2020 05; 92:105997.
    View on PubMed
  11. Borno HT, Rider JR, Gunn CM. The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing. JAMA Oncol. 2020 Mar 12.
    View on PubMed
  12. Cheung E, Borno HT. The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. J Oncol Pharm Pract. 2020 Jul; 26(5):1180-1189.
    View on PubMed
  13. Hala Borno, Tracy Kuo Lin, Anobel Y. Odisho, Arpita Desai, Vadim S Koshkin, Kalin Werner, Nichole Legaspi, Alexander Bell, Thomas Hope. Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):297-297.
    View on PubMed
  14. Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk Oh, Rahul Raj Aggarwal, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):502-502.
    View on PubMed
  15. Hala Borno, Christine Duffy, Sylvia Zhang, Zinnia Loya, Todd Golden, Debora Oh, Anobel Y. Odisho, Scarlett Lin Gomez. REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):207-207.
    View on PubMed
  16. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA. The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. J Racial Ethn Health Disparities. 2020 Feb 20.
    View on PubMed
  17. Daniel Kwon, Francis Wright, Li Zhang, Jonathan Chou, Hala Borno, Arpita Desai, David Yoonsuk Oh, YaoYao Guan Pollock, Rohit Bose, Franklin W. Huang, Thomas Hope, Terence W. Friedlander, Lawrence Fong, Felix Y Feng, Eric Jay Small, Rahul Raj Aggarwal, Vadim S Koshkin. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):187-187.
    View on PubMed
  18. Hala T. Borno, Eric J. Small, Li Zhang, Mindy C. DeRouen, Ann Griffin, Joseph McGuire, Charles J. Ryan, Robert A. Hiatt, Celia P. Kaplan. How current reporting practices may mask differences: a call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemporary Clinical Trials Communications. 2019 Dec 1; 16:100476.
    View on PubMed
  19. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93.
    View on PubMed
  20. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123.
    View on PubMed

Go to UCSF Profiles, powered by CTSI